CareDx(US:CDNA)2024-08-01 00:03Financial Performance - Total revenue reached $92.3 million, a 31% year-over-year increase[8] - Testing Services volume grew to 43,700 tests, a 17% year-over-year increase[8] - GAAP net loss was $1.4 million, while non-GAAP net income was $13.6 million, and adjusted EBITDA was $12.9 million[8] - Cash from operations generated $18.9 million, with cash, cash equivalents, and marketable securities totaling approximately $228.9 million[8] Guidance and Coverage - 2024 annual revenue guidance was raised to $320 million - $328 million, and adjusted EBITDA to a gain of $9 million to $15 million[8] - Coverage expanded by 27 million lives nationwide in the first half of 2024[8] Clinical Validation - The SHORE study demonstrated that HeartCare outperforms dd-cfDNA alone in identifying allograft rejection[8, 9, 12, 13, 14, 15, 16] - A Nature Medicine publication validated CareDx AlloView AI-enabled risk prediction model and demonstrated that AlloSure Kidney detects subclinical rejection in stable patients[8, 17, 18, 19, 20, 21, 22, 23] Revenue Growth - Adjusted Testing Services revenue increased by over 20% year-over-year[24] - Patient and Digital Solutions revenue increased by 19% to $10.7 million[26] - Products revenue increased by 35% to $10.6 million[27]